Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 5/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068698 | 0.84 | KDM4E (0.50) | SLC6A4SLC6A2AOC3SLC6A3MEN1 | |
| SCHEMBL25259285 | 0.84 | KDM4E (0.50) | SLC6A4SLC6A2AOC3SLC6A3MEN1 | |
| SCHEMBL25857480 | 0.82 | SLC6A4 (0.46) | SLC6A4SLC6A2AOC3CCR5SLC6A3 | |
| SCHEMBL25260933 | 0.82 | SLC6A4 (0.46) | SLC6A4SLC6A2AOC3SLC6A3 | |
| SCHEMBL31332659 | 0.70 | PNMT (0.44) | AOC3MEN1KMT2A | |
| SCHEMBL31332655 | 0.70 | PNMT (0.44) | AOC3MEN1KMT2A | |
| SCHEMBL25262299 | 0.68 | SLC6A2 (0.43) | SLC6A4SLC6A2AOC3 | |
| SCHEMBL31068677 | 0.68 | SLC6A2 (0.43) | SLC6A4SLC6A2AOC3 | |
| SCHEMBL25262310 | 0.67 | SLC6A2 (0.55) | SLC6A4SLC6A2AOC3SLC6A3 | |
| SCHEMBL31664244 | 0.67 | SLC6A2 (0.55) | SLC6A4SLC6A2AOC3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | SLC6A4 2807/4885SLC6A2 1803/4885AOC3 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.